Phase Ib/II Study of Ivosidenib Plus Venetoclax With or Without Azacitidine in Patients With IDH1-Mutated Hematologic Malignancies

May 29-31, 2020; Online at
Combination of ivosidenib plus venetoclax with or without azacitidine was well tolerated and effective in patients with IDH1-mutated hematologic malignancies.
Format: Microsoft PowerPoint (.ppt)
File Size: 240 KB
Released: June 1, 2020


Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
Bristol-Myers Squibb
Karyopharm Therapeutics

Related Content

Enter the characteristics of your patient with CLL into an online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Farrukh T. Awan, MD Jennifer R. Brown, MD, PhD Nicole Lamanna, MD Anthony Mato, MD, MSCE Jeff Sharman, MD Released: September 22, 2022

John M. Burke, MD; Shaji Kumar, MD; and Eunice S. Wang, MD, discuss their thoughts on key data in leukemias, lymphomas, and multiple myeloma presented at the 2022 American Society of Clinical Oncology Annual Meeting

John M. Burke, MD Shaji K. Kumar, MD Eunice S. Wang, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: September 13, 2022 Expired: September 12, 2023

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy into community care

Jesús G. Berdeja, MD Caron A. Jacobson, MD Released: September 12, 2022

In this commentary, experts answer questions on current therapeutic strategies and emerging data on the management of AML, from Clinical Care Options (CCO)

Naval G. Daver, MD Amir T. Fathi, MD Released: September 7, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings